Foghorn Therapeutics (FHTX) Change in Acquisitions & Divestments (2021 - 2026)

Foghorn Therapeutics' Change in Acquisitions & Divestments history runs 6 years deep, the most recent figure standing at $49.2 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 38.9% year-over-year to $49.2 million in Q1 2026; TTM through Mar 2026 was $212.0 million, a 16.72% decrease from a year earlier, with the FY2025 full-year figure at $243.3 million, up 4.67% from the prior year.
• Change in Acquisitions & Divestments grew to $49.2 million in Q1 2026 per FHTX's latest filing, from $47.2 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $80.6 million in Q1 2025 and bottomed at $19.0 million in Q2 2022.
• The 5-year median for Change in Acquisitions & Divestments is $53.1 million (2022), against an average of $53.6 million.
• Across the five-year window, Change in Acquisitions & Divestments plunged 79.89% in 2022 and jumped 303.02% in 2023, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $38.1 million in 2022, then rose by 16.17% to $44.3 million in 2023, then jumped by 41.02% to $62.4 million in 2024, then fell by 24.36% to $47.2 million in 2025, then grew by 4.25% to $49.2 million in 2026.
• Per Business Quant, the three latest FHTX Change in Acquisitions & Divestments figures stand at $49.2 million (Q1 2026), $47.2 million (Q4 2025), and $39.6 million (Q3 2025).